Genetic and Epigenetic Determinants of Low Dysferlin Expression in Monocytes

Human Mutation

Volumn 35, Issue 8, 2014, Pages 990-997

  Gallardo, Eduard ^a,b   Ankala, Arunkanth ^c   Núñez Álvarez, Yaiza ^d   Hegde, Madhuri ^c   Diaz Manera, Jordi ^a,b,e   Luna, Noemí De ^f,g   Pastoret, Ana ^a,b   Suelves, Mònica ^d   Illa, Isabel ^a,b,e  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Institut de Medicina Predictiva i Personalitzada del Cancer IMPPC   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

DYSF; Dysferlin; Methylation; Monocyte

Indexed keywords

DYSF PROTEIN, HUMAN; MEMBRANE PROTEIN; MUSCLE PROTEIN;

ADULT; AGED; BLOOD DONOR; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; HETEROZYGOTE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; SKELETAL MUSCLE;

ADULT; AGED; BLOOD DONORS; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; HETEROZYGOTE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION; PREDICTIVE VALUE OF TESTS;

EID: 84904384587     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22591     Document Type: Article

References (38)

1. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, et al. 1999. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8:855-861.
2. Angelini C, Grisold W, Nigro V. 2011. Diagnosis by protein analysis of dysferlinopathy in two patients mistaken as polymyositis. Acta Myol 30:185-187.
3. Ankala A, Nallamilli BR, Rufibach LE, Hwang E, Hegde MR. 2014. Diagnostic overview of blood-based dysferlin protein assay for dysferlinopathies. Muscle Nerve. 10.1002/mus.24195.
4. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP. 2003. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423:168-172.
5. Baylin SB, Jones PA. 2011. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11:726-734.
6. Bird A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21.
7. Blandin G, Beroud C, Labelle V, Nguyen K, Wein N, Hamroun D, Williams B, Monnier N, Rufibach LE, Urtizberea JA, Cau P, Bartoli M, et al. 2012. UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene. Hum Mutat 33:E2317-E2331.
8. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. 2006. DNA methylation: bisulphite modification and analysis. Nat Protoc 1:2353-2364.
9. De Luna N, Freixas A, Gallano P, Caselles L, Rojas-Garcia R, Paradas C, Nogales G, Dominguez-Perles R, Gonzalez-Quereda L, Vilchez JJ, Marquez C, Bautista J, et al. 2007. Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 17:69-76.
10. de Luna N, Gallardo E, Soriano M, Dominguez-Perles R, de la Torre C, Rojas-Garcia R, Garcia-Verdugo JM, Illa I. 2006. Absence of dysferlin alters myogenin expression and delays human muscle differentiation in vitro. J Biol Chem 281:17092-17098.
11. de Morree A, Flix B, Bagaric I, Wang J, van den Boogaard M, Grand Moursel L, Frants RR, Illa I, Gallardo E, Toes R, van der Maarel SM. 2013. Dysferlin regulates cell adhesion in human monocytes. J Biol Chem 288:14147-14157.
12. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, Miller J, Schlaeger T, et al. 2009. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41:1350-1353.
13. Fazzari MJ, Greally JM. 2004. Epigenomics: beyond CpG islands. Nat Rev Genet 5:446-455.
14. Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, et al. 2012. A DNA methylation fingerprint of 1628 human samples. Genome Res 22:407-419.
15. Foxton RM, Laval SH, Bushby KM. 2004. Characterisation of the dysferlin skeletal muscle promoter. Eur J Hum Genet 12:127-131.
16. Frederic MY, Lalande M, Boileau C, Hamroun D, Claustres M, Beroud C, Collod-Beroud G. 2009. UMD-predictor, a new prediction tool for nucleotide substitution pathogenicity - application to four genes: FBN1, FBN2, TGFBR1, and TGFBR2. Hum Mutat 30:952-959.
17. Gallardo E, de Luna N, Diaz-Manera J, Rojas-Garcia R, Gonzalez-Quereda L, Flix B, de Morree A, van der Maarel S, Illa I. 2011. Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy. PLoS One 6:e29061.
18. Gardiner-Garden M, Frommer M. 1987. CpG islands in vertebrate genomes. J Mol Biol 196:261-282.
19. Goll MG, Bestor TH. 2005. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 74:481-514.
20. Hermanova M, Zapletalova E, Sedlackova J, Chrobakova T, Letocha O, Kroupova I, Zamecnik J, Vondracek P, Mazanec R, Marikova T, Vohanka S, Fajkusova L. 2006. Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients. Muscle Nerve 33:424-432.
21. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, Brown Jr RH. 2002. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 51:129-133.
22. Illa I, De Luna N, Dominguez-Perles R, Rojas-Garcia R, Paradas C, Palmer J, Marquez C, Gallano P, Gallardo E. 2007. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology 68:1284-1289.
23. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, et al. 2009. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178-186.
24. Jones PA. 2012. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13:484-492.
25. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-692.
26. Krahn M, Beroud C, Labelle V, Nguyen K, Bernard R, Bassez G, Figarella-Branger D, Fernandez C, Bouvenot J, Richard I, Ollagnon-Roman E, Bevilacqua JA, et al. 2008. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 30:E345-E375.
27. Li LC, Dahiya R. 2002. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427-1431.
28. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, et al. 1998. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20:31-36.
29. Luna ND, Diaz-Manera J, Paradas C, Iturriaga C, Rojas-Garcia R, Araque J, Genebriera M, Gich I, Illa I, Gallardo E. 2012. 1alpha, 25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial. Mol Ther 20:1988-1997.
30. Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, Nishino I, Nonaka I, Arahata K, Brown RH, Jr. 2001. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 10:1761-1766.
31. Nagaraju K, Rawat R, Veszelovszky E, Thapliyal R, Kesari A, Sparks S, Raben N, Plotz P, Hoffman EP. 2008. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 172:774-785.
32. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. 2009. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 132:3175-3186.
33. Portela A, Esteller M. 2010. Epigenetic modifications and human disease. Nat Biotechnol 28:1057-1068.
34. Sharma S, Kelly TK, Jones PA. 2010. Epigenetics in cancer. Carcinogenesis 31:27-36.
35. Takai D, Jones PA. 2002. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99:3740-3745.
36. Vinit J, Samson M, Jr., Gaultier JB, Laquerriere A, Ollagnon E, Petiot P, Marie I, Levesque H, Rousset H. 2010. Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 29:103-106.
37. Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, Welch EM, Peltz SW, Barton ER, Brown RH, Jr., Sweeney HL. 2009. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol 109:901-905.
38. Xie W, Li M, Xu N, Lv Q, Huang N, He J, Zhang Y. 2013. MiR-181a regulates inflammation responses in monocytes and macrophages. PLoS One 8:e58639.